# A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

> **NCT02578641** · PHASE3 · COMPLETED · sponsor: **Tessa Therapeutics** · enrollment: 330 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** autologous EBV specific Cytotoxic T cells
- **DRUG:** combination IV gemcitabine and IV carboplatin (AUC2)

## Key facts

- **NCT ID:** NCT02578641
- **Lead sponsor:** Tessa Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02578641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02578641, "A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02578641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*